Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Moxalactam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.80 |
| ▸ | CMA1 | P23946 | 18/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxalactam SCHEMBL49015 | 1.00 | HSD17B10 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL30166493 | 1.00 | HSD17B10 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL20528908 | 0.99 | HSD17B10 (0.99) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL3511220 | 0.94 | HSD17B10 (0.88) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL194013 | 0.89 | PTGS1 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL14196602 | 0.89 | PTGS1 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL49016 | 0.89 | PTGS1 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL194012 | 0.89 | PTGS1 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL49017 | 0.89 | PTGS1 (1.00) | HSD17B10TDP1PTGS1CMA1 | |
| Moxalactam SCHEMBL951858 | 0.88 | PTGS1 (0.99) | HSD17B10TDP1PTGS1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | UNIV ARIZONA (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4628100-A2 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | Gregg, John Malcolm Hall (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250250647-A1 | STABLE CELL CLONES HARBORING REPLICATING SARS-COV-2 RNA | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2025-08-07 | — | — | US | disclosed |
| US-12285413-B2 | Anti-viral agents and methods for administration thereof | GREGG JOHN M H (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250099566-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | NATIONAL INSTITUTES OF HEALTH | 2025-03-27 | — | — | US | disclosed |
| CN-119351369-A | Protein LcSAT1 and application of related biological material thereof | 中国科学院植物研究所 | 2025-01-24 | — | — | CN | disclosed |
| CN-119307466-A | LcSFC6 protein and application of related biological material thereof | 中国科学院植物研究所 | 2025-01-14 | — | — | CN | disclosed |
| US-20240173456-A1 | THERAPEUTIC COMPOSITIONS FOR WOUND TREATMENT | ARIZONA BOARD OF REGENTS ON BEHALF OF NORTHERN ARIZONA UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| EP-3607084-B1 | A METHOD FOR TESTING ANTIMICROBIAL SUSCEPTIBILITY | UNIV WESTERN AUSTRALIA (AU) | 2024-05-01 | — | — | EP | disclosed |
| CN-115737573-B | Cephalosporium oxydanum freeze-dried powder for injection and preparation method thereof | 杭州沐源生物医药科技有限公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-1901795-A | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HUTCHINSON FRED CANCER RES (US) | 2007-01-24 | — | — | CN | disclosed |
| EP-1689228-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | Fred Hutchinson Cancer Research Center (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1684579-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1684580-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | Fred Hutchinson Cancer Research Center (US) | 2006-08-02 | — | — | EP | disclosed |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-08-04 | — | — | US | disclosed |
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | FRED HUTCHINSON CANCER RESEARCH CENTER | 2005-07-07 | — | — | US | disclosed |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-23 | — | — | US | disclosed |
| WO-2005041655-A1 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS, TISSUES, ORGANS, AND ORGANISMS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041656-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN TISSUES AND ORGANS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005039291-A2 | METHODS, COMPOSITIONS AND DEVICES FOR INDUCING STASIS IN CELLS | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050147692-A1 | Methods, compositions and devices for inducing stasis in tissues and organs | HIF1A, HIF1AN, PYGL | HSD17B10 3276/4885TDP1 3344/4885PTGS1 24/4885 |
| US-20050136125-A1 | Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms | HSF1, HSP90AB1, HSP90AA1 | HSD17B10 2858/4885TDP1 1116/4885PTGS1 54/4885 |
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | DNMT3L, DNMT3A, DNMT1 | HSD17B10 3634/4885TDP1 236/4885PTGS1 3474/4885 |
| US-20050170019-A1 | Methods, compositions and devices for inducing stasis in cells | PLAT, TBXA2R, THPO | HSD17B10 4427/4885TDP1 2119/4885PTGS1 19/4885 |
| US-12285413-B2 | Anti-viral agents and methods for administration thereof | ACE2, ACE, MAVS | HSD17B10 2827/4885TDP1 2443/4885PTGS1 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.